08:23 AM EDT, 09/05/2025 (MT Newswires) -- Theratechnologies ( THTX ) said Friday its new tesamorelin formulation, Egrifta WR, is now available following Food and Drug Administration approval earlier this year. The drug is used to reduce excess abdominal fat in adult patients with HIV and lipodystrophy.

The new version will gradually replace Egrifta SV. Egrifta WR requires weekly reconstitution and less than half the daily injection volume compared with Egrifta SV, which is reconstituted daily, the company said.

"Excess visceral abdominal fat is an increasingly important health concern for people living with HIV, and for the healthcare providers who treat them," said Christian Marsolais, chief medical officer.

"With Egrifta WR, we aim to simplify the management of excess visceral abdominal fat and enhance users' experience, as part of our commitment to helping people with HIV live their best lives."

Tesamorelin is the only FDA-approved treatment in the US for reducing excess abdominal fat in adults with HIV and lipodystrophy.

Theratechnologies ( THTX ) shares fell $0.02 to $3.23 in New York trading. They closed up $0.03 at $4.50 on the Toronto Stock Exchange on Thursday.